[go: up one dir, main page]

TW200626144A - Formulations of substituted benzoxazoles - Google Patents

Formulations of substituted benzoxazoles

Info

Publication number
TW200626144A
TW200626144A TW094142062A TW94142062A TW200626144A TW 200626144 A TW200626144 A TW 200626144A TW 094142062 A TW094142062 A TW 094142062A TW 94142062 A TW94142062 A TW 94142062A TW 200626144 A TW200626144 A TW 200626144A
Authority
TW
Taiwan
Prior art keywords
formulations
substituted benzoxazoles
manufacture
processes
benzoxazoles
Prior art date
Application number
TW094142062A
Other languages
English (en)
Inventor
James A Provost
Trevor I Armstrong
Zerina B Shafi
Marc S Tesconi
Mannching Sherry Ku
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of TW200626144A publication Critical patent/TW200626144A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
TW094142062A 2004-12-02 2005-11-30 Formulations of substituted benzoxazoles TW200626144A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US63237504P 2004-12-02 2004-12-02

Publications (1)

Publication Number Publication Date
TW200626144A true TW200626144A (en) 2006-08-01

Family

ID=36565706

Family Applications (1)

Application Number Title Priority Date Filing Date
TW094142062A TW200626144A (en) 2004-12-02 2005-11-30 Formulations of substituted benzoxazoles

Country Status (22)

Country Link
US (1) US20060121110A1 (zh)
EP (1) EP1850833A2 (zh)
JP (1) JP2008521919A (zh)
KR (1) KR20070089921A (zh)
CN (1) CN101128188A (zh)
AR (1) AR053653A1 (zh)
AU (1) AU2005311823A1 (zh)
BR (1) BRPI0518786A2 (zh)
CA (1) CA2589033A1 (zh)
CR (1) CR9144A (zh)
GT (1) GT200500349A (zh)
IL (1) IL183393A0 (zh)
MX (1) MX2007006564A (zh)
NI (1) NI200700139A (zh)
NO (1) NO20072636L (zh)
NZ (1) NZ555395A (zh)
PE (1) PE20061083A1 (zh)
RU (1) RU2007120253A (zh)
SV (1) SV2006002317A (zh)
TW (1) TW200626144A (zh)
WO (1) WO2006060532A2 (zh)
ZA (1) ZA200705011B (zh)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0608689A2 (pt) * 2005-03-08 2010-01-19 Wyeth Corp composto, composiÇço, processos para preparar monoidrato e a forma de cristal, e, uso de um monoidrato ou de uma forma de cristal
PE20071043A1 (es) * 2006-02-14 2007-10-23 Wyeth Corp FORMULACIONES FARMACEUTICAS ACUOSAS QUE COMPRENDE LIGANDOS SELECTIVOS DEL RECEPTOR DE ESTROGENO ERß
WO2007103873A2 (en) * 2006-03-06 2007-09-13 Wyeth Pharmaceutical formulations of an anhydrous crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol
AR059743A1 (es) * 2006-03-06 2008-04-23 Wyeth Corp Formulaciones farmaceuticas de una forma cristalina de monohidrato de 2- (3- fluor-4- hidroxifenil )-7- vinil-1,3- benzoaxol-5-ol
PE20071315A1 (es) * 2006-03-06 2008-02-14 Wyeth Corp Formulaciones de compuestos derivados de fenilo y procesos de preparacion para tabletas que contienen dichos compuestos
PE20071019A1 (es) * 2006-03-06 2007-10-29 Wyeth Corp Formulaciones farmaceuticas liquidas y semi-solidas que comprenden un modulador de receptores estrogenicos
US20080175901A1 (en) * 2006-11-21 2008-07-24 Wyeth Pharmaceutical formulations of a crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol
US20080241234A1 (en) * 2006-11-21 2008-10-02 Wyeth Pharmaceutical formulations of an anhydrate crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol
US20080175900A1 (en) * 2006-11-21 2008-07-24 Wyeth Pharmaceutical formulations of an anhydrate crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol
GB0814953D0 (en) * 2008-08-18 2008-09-24 Unilever Plc Improvements relating to nanodisperse compositions

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6331562B1 (en) * 1998-12-30 2001-12-18 Signal Pharmaceuticals, Inc. Compounds and methods for modulation of estrogen receptors
JP2004524289A (ja) * 2000-12-22 2004-08-12 アストラゼネカ・アクチエボラーグ 治療化合物
UA83620C2 (ru) * 2001-12-05 2008-08-11 Уайт Замещенные бензоксазолы и их аналоги как эстрогенные агенты
WO2003086319A2 (en) * 2002-04-10 2003-10-23 Merck & Co., Inc. Pharmaceutical compositions containing an hiv integrase inhibitor and a nonionic surfactant

Also Published As

Publication number Publication date
JP2008521919A (ja) 2008-06-26
SV2006002317A (es) 2006-06-26
CR9144A (es) 2007-11-23
IL183393A0 (en) 2007-09-20
CA2589033A1 (en) 2006-06-08
WO2006060532A2 (en) 2006-06-08
NO20072636L (no) 2007-08-13
BRPI0518786A2 (pt) 2008-12-09
RU2007120253A (ru) 2009-01-10
CN101128188A (zh) 2008-02-20
PE20061083A1 (es) 2006-11-14
WO2006060532A3 (en) 2006-11-16
GT200500349A (es) 2006-07-03
KR20070089921A (ko) 2007-09-04
US20060121110A1 (en) 2006-06-08
EP1850833A2 (en) 2007-11-07
AU2005311823A1 (en) 2006-06-08
NI200700139A (es) 2008-05-09
ZA200705011B (en) 2010-01-27
NZ555395A (en) 2009-07-31
AR053653A1 (es) 2007-05-16
MX2007006564A (es) 2007-06-19

Similar Documents

Publication Publication Date Title
BG108495A (en) 5-ht receptor ligands and uses thereof
MX2007003108A (es) Compuestos imidazo-3-il-amina sustituidos y biciclicos.
MY155317A (en) Benzene sulfonamide thiazole and oxazole compounds
NI200700139A (es) Formulaciones de benzoxazoles sustituidos
MY140826A (en) Substituted pyrazoline compounds, their preparation and use as medicaments.
TW200800967A (en) Benzimidazole thiophene compounds
SE0301700D0 (sv) Novel compounds
SI1888541T1 (sl) Benzo(d)izoksazol-3-il-aminske spojine in njihova uporaba kot ligandi vaniloidnega receptorja
MX2009010047A (es) Compuestos quimicos.
TW200626068A (en) Active compounds for seed treatment
MX2009010045A (es) Compuestos quimicos.
EP1633740A4 (en) CHEMICAL COMPOUNDS
MX2009007337A (es) Indazoles sustituidos con 5-piridinona.
TW200510317A (en) Caspase inhibitors and uses thereof
TW200600494A (en) Bisphenyl compounds useful as vitamin d3 receptor agonists
GEP20135959B (en) Aryl piperazine and their usage as alpha2c antagonists
TW200738659A (en) Novel compounds
MA31445B1 (fr) Composition à libération modifiée comprenant un dérivé de somatostatine en microparticules
MX2007006565A (es) Formulaciones de benzoxazoles sustituidos.
PL1758852T3 (pl) Podstawione związki cyklopentenu
TW200716618A (en) Chemical compounds
TW200700071A (en) Novel use
TW200640857A (en) Substituted pyrroles and imidazoles, compositions containing same, manufacturing process therefor and use thereof
PL1888514T3 (pl) Sole podstawionych estrów kwasu alofanowego i ich zastosowanie w środkach leczniczych
SG151306A1 (en) Novel benzothiazoles and the use thereof as medicaments